CytRx Corp. said Monday that it has enrolled its first patient ina Phase II trial investigating the safety and efficacy ofRheothRx Injection in sickle cell crisis.
The study is part of a multicenter trial under the direction ofBurroughs Wellcome Co., which has licensed worldwide rightsto the drug from Cytrx.
RheothRx Injection has been in Phase II studies for heartattack patients since March, the Norcross, Ga., company said.
(c) 1997 American Health Consultants. All rights reserved.